tiprankstipranks
Advertisement
Advertisement

MNKD Stock Latest News

MannKind price target lowered to $8 from $10 at Wedbush
The FlyMannKind price target lowered to $8 from $10 at Wedbush
19d ago
MNKD
UTHR
Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
PremiumMarket News
Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
25d ago
IBB
XBI
MannKind price target lowered to $7 from $8 at Wells Fargo
PremiumThe Fly
MannKind price target lowered to $7 from $8 at Wells Fargo
25d ago
MNKD
MannKind price target lowered to $8 from $11 at H.C. Wainwright
PremiumThe Fly
MannKind price target lowered to $8 from $11 at H.C. Wainwright
25d ago
MNKD
MannKind downgraded to Sector Perform from Outperform at RBC Capital
PremiumThe Fly
MannKind downgraded to Sector Perform from Outperform at RBC Capital
25d ago
MNKD
UTHR
MannKind reports Q4 EPS (5c) vs 3c last year
PremiumThe FlyMannKind reports Q4 EPS (5c) vs 3c last year
26d ago
MNKD
RBC says United Therapeutics TreSMI presents ‘material risk’ to MannKind
Premium
The Fly
RBC says United Therapeutics TreSMI presents ‘material risk’ to MannKind
27d ago
MNKD
UTHR
Leerink sees MannKind selloff as ‘overreaction’ to headline news
Premium
The Fly
Leerink sees MannKind selloff as ‘overreaction’ to headline news
27d ago
MNKD
UTHR
H.C. Wainwright sees MannKind selloff ‘potentially resetting’ value proposition
PremiumThe Fly
H.C. Wainwright sees MannKind selloff ‘potentially resetting’ value proposition
27d ago
MNKD
UTHR
United Therapeutics announces ‘category killer product’ Tresmi
PremiumThe Fly
United Therapeutics announces ‘category killer product’ Tresmi
27d ago
MNKD
UTHR
MannKind sinks after United Therapeutics announces soft-mist inhaler
PremiumThe Fly
MannKind sinks after United Therapeutics announces soft-mist inhaler
27d ago
MNKD
UTHR
Is MNKD a Buy, Before Earnings?
PremiumPre-Earnings
Is MNKD a Buy, Before Earnings?
28d ago
MNKD
MannKind: Pediatric Expansion, Improved Dosing, and Pipeline Diversification Drive Buy Rating on Afrezza Growth Potential
PremiumRatingsMannKind: Pediatric Expansion, Improved Dosing, and Pipeline Diversification Drive Buy Rating on Afrezza Growth Potential
1M ago
MNKD
MannKind says first patient enrolled in INHALE-1ST study of Afrezza
Premium
The Fly
MannKind says first patient enrolled in INHALE-1ST study of Afrezza
1M ago
MNKD
Morning Movers: USA Rare Earth surges after government funding pact
Premium
The Fly
Morning Movers: USA Rare Earth surges after government funding pact
2M ago
AAUC
CRWV
MannKind receives FDA approval for Afrezza dosage label
PremiumThe Fly
MannKind receives FDA approval for Afrezza dosage label
2M ago
MNKD
MannKind Targets Newly Diagnosed Youth With Afrezza: What Investors Should Watch
PremiumCompany Announcements
MannKind Targets Newly Diagnosed Youth With Afrezza: What Investors Should Watch
2M ago
MNKD
Multiple 2026 Regulatory, Pipeline, and Partnership Catalysts Underscore MannKind’s Underappreciated Growth Potential and Support Reiterated Buy Rating
PremiumRatings
Multiple 2026 Regulatory, Pipeline, and Partnership Catalysts Underscore MannKind’s Underappreciated Growth Potential and Support Reiterated Buy Rating
3M ago
MNKD
MannKind shares not pricing in ‘multiple tailwinds,’ says H.C. Wainwright
PremiumThe Fly
MannKind shares not pricing in ‘multiple tailwinds,’ says H.C. Wainwright
3M ago
MNKD
MannKind provides business updates, 2026 growth drivers
PremiumThe FlyMannKind provides business updates, 2026 growth drivers
3M ago
MNKD
3 ‘Strong Buy’ Stocks to Buy Today,12/24/2025, According to Top Analysts
Premium
Market News
3 ‘Strong Buy’ Stocks to Buy Today,12/24/2025, According to Top Analysts
3M ago
NOW
ENGN
MannKind announes FDA approval of sNDA for FUROSCIX On-body Infusor
Premium
The Fly
MannKind announes FDA approval of sNDA for FUROSCIX On-body Infusor
3M ago
MNKD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >